PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 - - Initial data... | May 18, 2023

Related Keywords

Canada ,Boston ,Massachusetts ,United States ,Laurence Watts ,James Mcarthur ,Gilmartin Group ,Pepgen Inc ,Health Canada ,Head Of Clinical Development At Pepgen ,Nasdaq ,Clinical Trial Application ,Michelle Mellion ,Clinical Development ,Drug Safety Monitoring Board ,Enhanced Delivery Oligonucleotide ,Private Securities Litigation Reform Act ,Pepgen Inc Stock Exchange ,News ,Information ,Press Release ,Hill ,Ssess ,Dystrophin ,Exon ,Skipping ,Data ,End ,Safety ,Following ,Multiple ,Doses ,F ,N ,Patients ,Ith ,Mutations ,Aamenable ,O ,1 ,Nitial Pepg Us7133171055 ,